share_log

Baird Maintains Outperform on Eiger BioPharmaceuticals, Raises Price Target to $5

Benzinga ·  Jun 30, 2023 09:43

Baird analyst Brian Skorney maintains Eiger BioPharmaceuticals (NASDAQ:EIGR) with a Outperform and raises the price target from $3 to $5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment